Top

Published in:

01-01-2015 | Original Article

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies

Authors: Margriet Oosterveld, Stefan Suciu, Petra Muus, Ulrich Germing, Michel Delforge, Amin Belhabri, Carlo Aul, Dominik Selleslag, Augustin Ferrant, Jean-Pierre Marie, Sergio Amadori, Ulrich Jehn, Franco Mandelli, Uwe Hess, Eva Hellström-Lindberg, Songuel Cakmak-Wollgast, Marco Vignetti, Boris Labar, Roel Willemze, Theo de Witte

Published in: Annals of Hematology | Issue 1/2015

Abstract

High-risk myelodysplastic syndrome (MDS) patients have usually a less favorable outcome after intensive treatment compared with de novo acute myeloid leukemia (AML) patients. This may reflect different disease-related and patient-related factors. The purpose of this analysis is to identify disease-specific prognostic factors and to develop prognostic scores for both patient groups. A total of 692 patients in the EORTC/GIMEMA AML-10 study and 289 patients in the CRIANT study received identical remission-induction and consolidation treatment. Estimated 5-year survival rate was 34 % in the AML-10 versus 27 % in the CRIANT study, and estimated disease-free survival was 40 % versus 28 %, respectively. In multivariate analysis, cytogenetic characteristics, white blood count, and age appeared prognostic for survival in both studies. French-American-British (FAB) subtype and performance status were prognostic in the AML-10 study only, whereas number of cytopenias and duration of antecedent hematologic disorder >6 months were prognostic in the CRIANT study only. The prognostic scores distinguish three groups with a 5-year survival rate of 54, 38, and 19 % in the AML-10 study versus 69, 37, and 5 % in the CRIANT study. The prognostic value of these scores has been validated on two external series. The new scoring systems form a practical tool to predict the outcome of individual MDS and AML patients treated with intensive antileukemic therapy.

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:189–199PubMedCrossRef

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620–625PubMedCrossRef

Kahl C, Florschutz A, Muller G, Jentsch-Ullrich K, Arland M, Leuner S, Franke A, Hoffkes HG (1997) Prognostic significance of dysplastic features of hematopoiesis in patients with de novo acute myelogenous leukemia. Ann Hematol 75:91–94PubMedCrossRef

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (2000) The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol 13:193–207PubMedCrossRef

Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217–223PubMedCrossRef

Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De RG, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102:1232–1240PubMedCrossRef

Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M (1996) A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 88:2841–2851PubMed

Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH, Harrison G (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118:385–400PubMedCrossRef

Burnett AK, Hills RK, Milligan DW, Goldstone AH, Prentice AG, McMullin MF, Duncombe A, Gibson B, Wheatley K (2010) Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 28:586–595PubMedCrossRef

10.

Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E III (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331:896–903PubMedCrossRef

11.

Bishop JF, Matthews JP, Young GA, Szer J, Gillett A, Joshua D, Bradstock K, Enno A, Wolf MM, Fox R, Cobcroft R, Herrmann R, Van Der WM, Lowenthal RM, Page F, Garson OM, Juneja S (1996) A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87:1710–1717PubMed

12.

Stone RM (2009) How I treat patients with myelodysplastic syndromes. Blood 113:6296–6303PubMedCrossRef

13.

Malcovati L, Hellstrom-Lindberg E, Bowen D, Ades L, Cermak J, Del CC, la Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M (2013) Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 122:2943–2964PubMedCentralPubMedCrossRef

14.

de Witte T, Muus P, De Pauw B, Haanen C (1990) Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia. Cancer 66:831–837PubMedCrossRef

15.

Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M (1997) Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 90:2969–2977PubMed

16.

de Witte T, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, Jaksic B, Selleslag D, Zittoun R, Dardenne M (1995) Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG). Leukemia 9:1805–1811PubMed

17.

Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F (1991) Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 77:497–501PubMedCrossRef

18.

Parker JE, Pagliuca A, Mijovic A, Cullis JO, Czepulkowski B, Rassam SM, Samaratunga IR, Grace R, Gover PA, Mufti GJ (1997) Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 99:939–944PubMedCrossRef

19.

Wattel E, Solary E, Leleu X, Dreyfus F, Brion A, Jouet JP, Hoang-Ngoc L, Maloisel F, Guerci A, Rochant H, Gratecos N, Casassus P, Janvier M, Brice P, Lepelley P, Fenaux P (1999) A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Francais des Myelodysplasies. Group Ouest-Est d'etude des Leucemies aigues myeloides. Leukemia 13:524–529PubMedCrossRef

20.

de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Boogaerts M, Zittoun R, Gratwohl A, Zwierzina H, Hagemeijer A, Willemze R (2001) Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 98:2326–2331PubMedCrossRef

21.

Appelbaum FR, Anderson J (1998) Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia 12(Suppl 1):S25–S29PubMed

22.

de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P, Gratwohl A, Runde V (2000) Niederwieser D, van BA, Devergie A, Cornelissen J, Jouet JP, Arnold R, Apperley J: Haematopoietic stem cell transplantation for patients with myelo-dysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 110:620–630PubMedCrossRef

23.

Kantarjian H, O'Brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106:1090–1098PubMedCrossRef

24.

Appelbaum FR, Kopecky KJ (1997) Long-term survival after chemotherapy for acute myeloid leukemia: the experience of the Southwest Oncology Group. Cancer 80:2199–2204PubMedCrossRef

25.

Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Burnett AK (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116:354–365PubMedCrossRef

26.

Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325–4336PubMedCrossRef

27.

Kern W, Haferlach T, Schoch C, Loffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, Buchner T, Hiddemann W (2003) Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 101:64–70PubMedCrossRef

28.

Gupta V, Chun K, Yi QL, Minden M, Schuh A, Wells R, Brandwein J (2005) Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer 103:2082–2090PubMedCrossRef

29.

Hast R, Hellstrom-Lindberg E, Ohm L, Bjorkholm M, Celsing F, Dahl IM, Dybedal I, Gahrton G, Lindberg G, Lerner R, Linder O, Lofvenberg E, Nilsson-Ehle H, Paul C, Samuelsson J, Tangen JM, Tidefelt U, Turesson I, Wahlin A, Wallvik J, Winquist I, Oberg G, Bernell P (2003) No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia 17:1827–1833PubMedCrossRef

30.

Germing U, Hildebrandt B, Pfeilstocker M, Nosslinger T, Valent P, Fonatsch C, Lubbert M, Haase D, Steidl C, Krieger O, Stauder R, Giagounidis AA, Strupp C, Kundgen A, Mueller T, Haas R, Gattermann N, Aul C (2005) Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 19:2223–2231PubMedCrossRef

31.

de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellstrom-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R (2010) Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 95:1754–1761PubMedCentralPubMedCrossRef

32.

Mandelli F, Vignetti M, Suciu S, Stasi R, Petti MC, Meloni G, Muus P, Marmont F, Marie JP, Labar B, Thomas X, Di RF, Willemze R, Liso V, Ferrara F, Baila L, Fazi P, Zittoun R, Amadori S, de Witte T (2009) Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. J Clin Oncol 27:5397–5403PubMedCentralPubMedCrossRef

33.

Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I (2004) High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 64:6337–6343PubMedCrossRef

34.

Klein JP, Moeschberger ML (1997) Survival analysis: techniques for censored and truncated data. Statistics for Biology and Health. Springer, New YorkCrossRef

35.

Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef

36.

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89:2079–2088PubMed

37.

Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, la Porta MG, Nomdedeu B, Arenillas L, Luno E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G (2013) Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood 121:3005–3015PubMedCrossRef

38.

Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, Storer B (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 106:2912–2919PubMedCentralPubMedCrossRef

39.

Naqvi K, Garcia-Manero G, Sardesai S, Oh J, Vigil CE, Pierce S, Lei X, Shan J, Kantarjian HM, Suarez-Almazor ME (2011) Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol 29:2240–2246PubMedCentralPubMedCrossRef

40.

Raza A, Mundle S, Shetty V, Alvi S, Chopra H, Span L, Parcharidou A, Dar S, Venugopal P, Borok R, Gezer S, Showel J, Loew J, Robin E, Rifkin S, Alston D, Hernandez B, Shah R, Kaizer H, Gregory S, Preisler H (1996) A paradigm shift in myelodysplastic syndromes. Leukemia 10:1648–1652PubMed

41.

Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96:3932–3938PubMed

42.

Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjian HM, Rogers A, Jilani I, Lin CW, Pierce S, Freireich EJ, Estey EH (2002) Myelodysplastic syndrome is not merely "preleukemia". Blood 100:791–798PubMedCrossRef

43.

Lepelley P, Soenen V, Preudhomme C, Lai JL, Cosson A, Fenaux P (1994) Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 8:998–1004PubMed

44.

Sato H, Gottesman MM, Goldstein LJ, Pastan I, Block AM, Sandberg AA, Preisler HD (1990) Expression of the multidrug resistance gene in myeloid leukemias. Leuk Res 14:11–21PubMedCrossRef

45.

Sonneveld P, van Dongen JJ (1993) Hagemeijer A, van LK, Nooter K, Schoester M, Adriaansen HJ, Tsuruo T, de LK: High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 7:963–969PubMed

46.

Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. Southwest Oncol Group Study Blood 89:3323–3329

47.

Shetty V, Mundle S, Alvi S, Showel M, Broady-Robinson L, Dar S, Borok R, Showel J, Gregory S, Rifkin S, Gezer S, Parcharidou A, Venugopal P, Shah R, Hernandez B, Klein M, Alston D, Robin E, Dominquez C, Raza A (1996) Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 20:891–900PubMedCrossRef

48.

Bouscary D, De VJ, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M (1997) Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11:839–845PubMedCrossRef

49.

Keating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R (2003) The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial. Leukemia 17:60–67PubMedCrossRef

50.

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstocker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454–2465PubMedCrossRef

51.

Oosterveld M, Wittebol SH, Lemmens WA, Kiemeney BA, Catik A, Muus P, Schattenberg AV, de Witte TJ (2003) The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups. Br J Haematol 123:81–89PubMedCrossRef

52.

Knipp S, Hildebrand B, Kundgen A, Giagounidis A, Kobbe G, Haas R, Aul C, Gattermann N, Germing U (2007) Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer 110:345–352PubMedCrossRef

53.

Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M (2009) Stevens-Linders E, van HP, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH: Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838–842PubMedCrossRef

54.

Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, Tonnissen ER, van der HA, Scheele TN, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665–667PubMedCrossRef

55.

Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453–474PubMedCrossRef

56.

Moeschberger ML, Klein JP (1995) Statistical methods for dependent competing risks. Lifetime Data Anal 1:195–204PubMedCrossRef

57.

Li Z, Herold T, He C, Valk PJ, Chen P, Jurinovic V, Mansmann U, Radmacher MD, Maharry KS, Sun M, Yang X, Huang H, Jiang X, Sauerland MC, Buchner T, Hiddemann W, Elkahloun A, Neilly MB, Zhang Y, Larson RA, Le Beau MM, Caligiuri MA, Dohner K, Bullinger L, Liu PP, Delwel R, Marcucci G, Lowenberg B, Bloomfield CD, Rowley JD, Bohlander SK, Chen J (2013) Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study. J Clin Oncol 31:1172–1181PubMedCentralPubMedCrossRef

Title: Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies
Authors: Margriet Oosterveld
Stefan Suciu
Petra Muus
Ulrich Germing
Michel Delforge
Amin Belhabri
Carlo Aul
Dominik Selleslag
Augustin Ferrant
Jean-Pierre Marie
Sergio Amadori
Ulrich Jehn
Franco Mandelli
Uwe Hess
Eva Hellström-Lindberg
Songuel Cakmak-Wollgast
Marco Vignetti
Boris Labar
Roel Willemze
Theo de Witte
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 1/2015
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-014-2177-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

The use of anti-fibrinolytic agents in patients with HHT: a retrospective survey

Hemophagocytic lymphohistiocytosis secondary to Falciparum malaria in a 5 year-old boy

Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients

HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?

Diagnostic value of bronchoscopy in patients with hematologic malignancy and pulmonary infiltrates

Impact of active surveillance, chlorambucil, and other therapy on health-related quality of life in patients with CLL/SLL in the Netherlands

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials